Tag: preparedness

Press Release

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality.

Build real-world resilience with a simple, category-based system that covers emergency food, portable water filtration, solar power, and off-grid heating—designed for modern families facing blackouts, disasters, or disruptions in 2025.

As the world fixates on cyber warfare, grid instability, and rising tensions in the Middle East, a quieter alarm is sounding beneath the headlines. It doesn’t come from mainstream media, but from former defense insiders and everyday Americans quietly preparing for a different kind of threat — one that won’t announce itself with sirens or headlines. That’s the driving force behind Dark Reset: Survival Before the Silence, a civilian resilience system based on the belief that the next collapse won’t start with fire — it’ll start with silence.

COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million.

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

Allschwil, Switzerland, July 29, 2025